Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 10, 2021

SELL
$14.81 - $19.13 $440,597 - $569,117
-29,750 Closed
0 $0
Q1 2021

May 07, 2021

BUY
$14.52 - $23.53 $17,424 - $28,236
1,200 Added 4.2%
29,750 $530,000
Q4 2020

Feb 10, 2021

SELL
$10.14 - $15.19 $29,406 - $44,051
-2,900 Reduced 9.22%
28,550 $408,000
Q3 2020

Nov 02, 2020

BUY
$9.57 - $21.32 $33,973 - $75,686
3,550 Added 12.72%
31,450 $318,000
Q2 2020

Aug 10, 2020

SELL
$12.21 - $16.99 $97,069 - $135,070
-7,950 Reduced 22.18%
27,900 $411,000
Q1 2020

May 05, 2020

SELL
$9.03 - $19.72 $199,563 - $435,812
-22,100 Reduced 38.14%
35,850 $479,000
Q4 2019

Feb 14, 2020

SELL
$13.01 - $17.15 $78,710 - $103,757
-6,050 Reduced 9.45%
57,950 $817,000
Q3 2019

Nov 05, 2019

BUY
$14.55 - $20.56 $10,185 - $14,392
700 Added 1.11%
64,000 $1.05 Million
Q2 2019

Aug 13, 2019

SELL
$15.0 - $19.62 $22,500 - $29,430
-1,500 Reduced 2.31%
63,300 $993,000
Q1 2019

May 13, 2019

SELL
$11.65 - $17.72 $43,105 - $65,564
-3,700 Reduced 5.4%
64,800 $1.13 Million
Q4 2018

Jan 29, 2019

SELL
$10.72 - $16.73 $49,312 - $76,958
-4,600 Reduced 6.29%
68,500 $763,000
Q3 2018

Nov 13, 2018

SELL
$17.73 - $26.69 $43,438 - $65,390
-2,450 Reduced 3.24%
73,100 $1.78 Million
Q2 2018

Aug 02, 2018

SELL
$10.79 - $24.44 $11,868 - $26,884
-1,100 Reduced 1.44%
75,550 $1.37 Million
Q1 2018

May 04, 2018

SELL
$9.0 - $20.16 $19,800 - $44,352
-2,200 Reduced 2.79%
76,650 $856,000
Q4 2017

Feb 08, 2018

BUY
$13.26 - $22.86 $23,868 - $41,148
1,800 Added 2.34%
78,850 $1.53 Million
Q3 2017

Nov 08, 2017

BUY
$19.76 - $24.9 $30,628 - $38,595
1,550 Added 2.05%
77,050 $1.67 Million
Q2 2017

Aug 11, 2017

BUY
N/A
75,500
75,500 $0

Others Institutions Holding OMER

About OMEROS CORP


  • Ticker OMER
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,730,000
  • Market Cap $684M
  • Description
  • Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical program...
More about OMER
Track This Portfolio

Track D.A. Davidson & Co. Portfolio

Follow D.A. Davidson & Co. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

News

Stay updated on D.A. Davidson & Co. with notifications on news.